-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UsNw5H/SR5KI0S0Nnke3hX6Nxa4f2gr+9HkfUWbFf8Qtt72MzNzJWHpbmAjlAcmq T+Kgsnxy1B13uUPRIPKRvw== 0000217028-02-000004.txt : 20020414 0000217028-02-000004.hdr.sgml : 20020414 ACCESSION NUMBER: 0000217028-02-000004 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020212 GROUP MEMBERS: AVENTIS PHARMACEUTICALS INC. GROUP MEMBERS: HMR PHARMA INC. FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RHONE POULENC RORER INC CENTRAL INDEX KEY: 0000217028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 231699163 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 500 ARCOLA RD STREET 2: P O BOX 1200 M/S 5B14 CITY: COLLEGEVILLE STATE: PA ZIP: 19426-0107 BUSINESS PHONE: 6104548000 FORMER COMPANY: FORMER CONFORMED NAME: RORER GROUP INC DATE OF NAME CHANGE: 19900731 FORMER COMPANY: FORMER CONFORMED NAME: RORER AMCHEM INC DATE OF NAME CHANGE: 19770604 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALBANY MOLECULAR RESEARCH INC CENTRAL INDEX KEY: 0001065087 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 141742717 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-57327 FILM NUMBER: 02535934 BUSINESS ADDRESS: STREET 1: 21 CORPORATE CIRCLE STREET 2: P O BOX 15098 CITY: ALBANY STATE: NY ZIP: 12203-5154 BUSINESS PHONE: 5184640279 MAIL ADDRESS: STREET 1: 21 CORPORATE CIRCLE STREET 2: P O BOX 15098 CITY: ALBANY STATE: NY ZIP: 12203-5154 SC 13G/A 1 albany-13ga.txt ALBANY MOLECULAR 13G A =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Albany Molecular Research, Inc. --------------------------------------- (Name of Issuer) COMMON STOCK, $.01 PAR VALUE --------------------------------------------------------------------------- (Title of Class of Securities) 012423 10 9 ----------------- (CUSIP Number) December 31, 2001 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ x ] Rule 13d-1(d) =========================================================================== - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With _________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of _______________________________________________ Shares Beneficially 6) Shared Voting 0 Owned by _______________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- This Amendment No. 1 to Statement on Schedule 13G with respect to the Common Stock of Albany Molecular Research, Inc. (the "Issuer"), is filed solely to amend Item 5(e), to set forth that during the year ended December 31, 2001, Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - -------------------------------------------------------------------------------- (e) API and Pharma each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer during the year ended on December 31, 2001. SIGNATURES ------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: February 8, 2002 By: /s/ Edward H. Stratemeier -------------------------- Edward H. Stratemeier Vice President After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: February 8, 2002 By: /s/ Phillip R. Ridolfi ----------------------------------- Phillip R. Ridolfi President -----END PRIVACY-ENHANCED MESSAGE-----